ARTICLE | Company News
Ipsen, Oncodesign deal
January 9, 2012 8:00 AM UTC
Ipsen and Oncodesign partnered to discover and develop leucine-rich repeat kinase 2 (LRRK2) inhibitors to treat Parkinson's disease (PD) and other diseases using Oncodesign's Nanocyclix technology. I...